Short description
Myonexus Therapeutics is a clinical stage gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy types.
Description
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy (LGMD) Types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital, a global leader in muscular dystrophy gene therapy discovery and translational research.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Columbus, Ohio, United States, North America
Founded on
February 1, 2017
Closed on
February 7, 2019
Exited on
February 27, 2019
Non-profit?
No
Acquired?
No
Employees count
11-50
Investors
Noaccess, Cannot Access, Absolutely Noaccess, Nopepepe, Absolutely Noaccess
Sign in for full access
Founders
Michael Triplett